10:30 AM: Bristol-Myers Squibb revealed its plans to move beyond key patent expires later this decade. In the company’s presentation Monday morning, Bristol’s Executive Vice President and Chief Commercial Officer Chris Boerner, Ph.D. said the pharma titan expects annual sales to rise by low- to mid-single digits over the course of 2020 to 2025.
In-line brands such as the Pfizer-partnered blood thinner, Eliquis, ought to contribute $8 billion to $10 billion in sales growth over this five-year period. Meanwhile, newer product launches ought to deliver between $10 billion to $13 billion in additional sales during the same time frame.
Looking forward, Boerner said the company’s late-stage pipeline has the potential to deliver upwards of $10 billion in risk-adjusted sales in the second half of the decade. BMS's vice president highlighted six late-stage product candidates as key growth drivers for the company in the back half of the decade: (milvexian, iberdomide, mezigdomide, BMS-986278, repotrectinib and cendakimab).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.